Atrys Health (ATRY) Q2 2025 earnings summary

Executive summary

• H1 2025 revenue rose 7.8% YoY to €115.8M, led by Oncology (+16.9%) and Diagnostics (+9.8%).

• Operating profit turned positive at €1.1M; net loss attributable to the parent narrowed to €9.3M from €16.5M.

• Strategic priorities include organic growth in high-potential areas, portfolio focus, asset divestments, and debt reduction.

Financial highlights

• Gross margin was €73.9M, or 63.7% of revenue, versus 67.2% in H1 2024.

• Adjusted EBITDA fell 13.3% to €21.9M, but grew 3.4% excluding lower R&D grant income.

• Adjusted operating cash flow declined 18.2% to €15.7M, mainly due to lower grants and higher expansion CAPEX.

• Consolidated operating income was €1.1M, compared with an operating loss in H1 2024; net financial expenses were €10.6M.

• Period-end cash and cash equivalents were €13.6M, down from €20.4M at the start of the year.

Outlook and guidance

• Focus on organic growth in strategic geographies and business lines, operational efficiency, and internationally scalable businesses with stronger cash generation.

• Strategic review includes possible divestments of non-core assets to reduce debt and maximize shareholder value.

• Management expected to recover part of the Medical Oncology Spain margin decline in Q4 through contract renegotiations; two Mexico center openings were planned for H2 2025.